Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.

Citation metadata

Publisher: American Medical Association
Document Type: Report
Length: 56 words

Document controls

Main content

Abstract :

Treatment with canakinumab, compared with placebo, might not remarkably boost the likelihood of survival without invasive mechanical ventilation (IMV) among patients hospitalized with severe COVID-19. The patients also have elevated C-reactive protein or ferritin levels. In 454 patients, treatment with intravenous canakinumab vs. placebo led to survival without IMV at 29 days of 88.8% vs 85.7%.

Source Citation

Source Citation   

Gale Document Number: GALE|A679725350